Eligibility Type 2 Diabetes Mellitus NCT00393770

Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
at least three of these
Beschrijving

criteria Three Minimum

Datatype

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C0205449
UMLS CUI [1,3]
C1524031
relatives with type 2 diabetes
Beschrijving

Non-Insulin-Dependent Diabetes Mellitus Relative

Datatype

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0080103
age between 40 and 65 years
Beschrijving

Age

Datatype

boolean

Alias
UMLS CUI [1]
C0001779
systolic and diastolic pressure ≥ 140 or ≥90 mmhg respectively
Beschrijving

Systolic Pressure | Diastolic blood pressure

Datatype

boolean

Alias
UMLS CUI [1]
C0871470
UMLS CUI [2]
C0428883
body mass index ≥25 for men and ≥24 for women
Beschrijving

Body mass index | Gender

Datatype

boolean

Alias
UMLS CUI [1]
C1305855
UMLS CUI [2]
C0079399
triglycerides ≥200 mg/dl
Beschrijving

Triglycerides

Datatype

boolean

Alias
UMLS CUI [1]
C0041004
serum creatinine ≤1.5 mg/dl, proteinuria ≤ 0.5g/24h
Beschrijving

Creatinine measurement, serum | Proteinuria

Datatype

boolean

Alias
UMLS CUI [1]
C0201976
UMLS CUI [2]
C0033687
capacity to understand the scope and the risks of the study
Beschrijving

Comprehension Study Protocol

Datatype

boolean

Alias
UMLS CUI [1,1]
C0162340
UMLS CUI [1,2]
C2348563
written informed consent
Beschrijving

Informed Consent

Datatype

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
concomitant treatment with steroids, anti-inflammatory and immunosuppressive drug, and any other drug acting on insulin sensitivity and/or insulin secretion, particularly glitazones and other oral hypoglycemic drug
Beschrijving

Steroids | Anti-Inflammatory Agents | Immunosuppressive Agents | Pharmaceutical Preparations Insulin Sensitivity | Pharmaceutical Preparations insulin secretion | Thiazolidinediones | Oral hypoglycemic

Datatype

boolean

Alias
UMLS CUI [1]
C0038317
UMLS CUI [2]
C0003209
UMLS CUI [3]
C0021081
UMLS CUI [4,1]
C0013227
UMLS CUI [4,2]
C0920563
UMLS CUI [5,1]
C0013227
UMLS CUI [5,2]
C1256369
UMLS CUI [6]
C1257987
UMLS CUI [7]
C0359086
treatment with l-acetylcarnitine in the six months before the study
Beschrijving

Acetylcarnitine

Datatype

boolean

Alias
UMLS CUI [1]
C0001040
previous or concomitant treatment with metformin
Beschrijving

Metformin

Datatype

boolean

Alias
UMLS CUI [1]
C0025598
legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequences of the trial.
Beschrijving

Comprehension Study Protocol Unable

Datatype

boolean

Alias
UMLS CUI [1,1]
C0162340
UMLS CUI [1,2]
C2348563
UMLS CUI [1,3]
C1299582

Similar models

Eligibility Type 2 Diabetes Mellitus NCT00393770

Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
criteria Three Minimum
Item
at least three of these
boolean
C0243161 (UMLS CUI [1,1])
C0205449 (UMLS CUI [1,2])
C1524031 (UMLS CUI [1,3])
Non-Insulin-Dependent Diabetes Mellitus Relative
Item
relatives with type 2 diabetes
boolean
C0011860 (UMLS CUI [1,1])
C0080103 (UMLS CUI [1,2])
Age
Item
age between 40 and 65 years
boolean
C0001779 (UMLS CUI [1])
Systolic Pressure | Diastolic blood pressure
Item
systolic and diastolic pressure ≥ 140 or ≥90 mmhg respectively
boolean
C0871470 (UMLS CUI [1])
C0428883 (UMLS CUI [2])
Body mass index | Gender
Item
body mass index ≥25 for men and ≥24 for women
boolean
C1305855 (UMLS CUI [1])
C0079399 (UMLS CUI [2])
Triglycerides
Item
triglycerides ≥200 mg/dl
boolean
C0041004 (UMLS CUI [1])
Creatinine measurement, serum | Proteinuria
Item
serum creatinine ≤1.5 mg/dl, proteinuria ≤ 0.5g/24h
boolean
C0201976 (UMLS CUI [1])
C0033687 (UMLS CUI [2])
Comprehension Study Protocol
Item
capacity to understand the scope and the risks of the study
boolean
C0162340 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
Informed Consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Steroids | Anti-Inflammatory Agents | Immunosuppressive Agents | Pharmaceutical Preparations Insulin Sensitivity | Pharmaceutical Preparations insulin secretion | Thiazolidinediones | Oral hypoglycemic
Item
concomitant treatment with steroids, anti-inflammatory and immunosuppressive drug, and any other drug acting on insulin sensitivity and/or insulin secretion, particularly glitazones and other oral hypoglycemic drug
boolean
C0038317 (UMLS CUI [1])
C0003209 (UMLS CUI [2])
C0021081 (UMLS CUI [3])
C0013227 (UMLS CUI [4,1])
C0920563 (UMLS CUI [4,2])
C0013227 (UMLS CUI [5,1])
C1256369 (UMLS CUI [5,2])
C1257987 (UMLS CUI [6])
C0359086 (UMLS CUI [7])
Acetylcarnitine
Item
treatment with l-acetylcarnitine in the six months before the study
boolean
C0001040 (UMLS CUI [1])
Metformin
Item
previous or concomitant treatment with metformin
boolean
C0025598 (UMLS CUI [1])
Comprehension Study Protocol Unable
Item
legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequences of the trial.
boolean
C0162340 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])